Transgenic Nonhuman Animal (e.g., Mollusks, Etc.) Patents (Class 800/13)
-
Publication number: 20140359795Abstract: Livestock with sperm labeled to indicate an X and/or Y chromosome. Male livestock that produce progeny of only one gender. Sperm that have a marker.Type: ApplicationFiled: April 28, 2014Publication date: December 4, 2014Inventors: Scott C. Fahrenkrug, Daniel F. Carlson
-
Publication number: 20140335579Abstract: The present invention relates to polynucleotides from Cochliobolus heterostrophus C5, Cyanothece sp. CCY0110, Mycocentrospora acerin and Hyaloperonospora parasitica, which code for desaturases and which can be employed for the recombinant production of polyunsaturated fatty acids. The invention furthermore relates to vectors, host cells and transgenic nonhuman organisms which comprise the polynucleotides according to the invention, and to the polypeptides encoded by the polynucleotides. The invention furthermore relates to antibodies against the polypeptides according to the invention. Finally, the invention also relates to production processes for the polyunsaturated fatty acids and for oil, lipid and fatty acid compositions and to their use as drugs, cosmetics, foodstuffs, feedstuffs, preferably fish food, or food supplements.Type: ApplicationFiled: July 23, 2014Publication date: November 13, 2014Inventors: Toralf Senger, Jörg Bauer, Johnathan A. Napier
-
Publication number: 20140338007Abstract: Transgenic artiodactyls are described as well as methods of making and using such artiodactyls.Type: ApplicationFiled: July 14, 2014Publication date: November 13, 2014Applicant: Recombinetics, Inc.Inventors: Scott C. Fahrenkrug, Daniel F. Carlson, Aron M. Geurts
-
Patent number: 8883150Abstract: The present invention provides a high affinity, antigen-specific, soluble heavy chain-only antibody which: lacks hallmark camelid-related amino acid substitutions and has FR2 substitutions which are not found in antibodies which comprise heavy and light chain; shows increased net hydrophobicity within CDR1 and an increased number of charged amino acids present in CDR3; and comprises one or more amino acid substitutions within the framework ?-pleated sheet leading to increased net hydrophobicity within FR1 and increased number of charged amino acids present in FR3. Also provided are VH domains having the same properties, gene segments for their production, methods for their production, transgenic animals and uses of the antibody of the VH domains in therapy.Type: GrantFiled: March 19, 2010Date of Patent: November 11, 2014Assignee: Erasmus University Medical CenterInventors: Roger Kingdon Craig, Franklin Gerardus Grosveld, Richard Wilhelm Janssens, Dubravka Drabek, Tao Chen, Ernie De Boer
-
Publication number: 20140331342Abstract: The present invention develops a novel method for controlling mosquito populations. Culicinae mosquitoes carrying one or more loci of transformant Tra-2 RNAi constructs which target to mosquito Transformer-2 locus in respective or none respective Culicinae mosquitoes. Tra-2 sequences used to assemble Tra-2 RNAi recombinant constructs are Tra-2 gene sequences of Culicinae mosquitoes and can be derived from endogenous or exogenous sequences. The Tra-2 RNAi expression is conditional, wherein the expression causing a knockdown effect into the endogenous Tra-2 gene results in mortality of X (m) chromosome bearing sperms and produces maleness mosquito population in the nature environmental of the species.Type: ApplicationFiled: December 29, 2011Publication date: November 6, 2014Inventors: Duong Thanh Hoang, Kim Phuc Hoang
-
Publication number: 20140325691Abstract: The present invention provides methods for modulating expression of endogenous cellular genes using recombinant zinc finger proteins.Type: ApplicationFiled: June 5, 2014Publication date: October 30, 2014Applicant: Sangamo BioSciences, Inc.Inventors: George Norbert Cox III, Casey C. Case, Stephen P. Eisenberg, Eric Edward Jarvis, Sharon Kaye Spratt
-
Publication number: 20140325692Abstract: The present invention provides methods for light-dependent gene regulation using a light-responsive DNA-binding protein. Also provided are related nucleic acid molecules, and protein molecules, such as those encoding or comprising the light-responsive DNA-binding protein or DNA-binding sites recognizing the light-responsive DNA-binding protein. Kits using the present light-dependent gene regulation system are further provided by the present invention.Type: ApplicationFiled: November 16, 2012Publication date: October 30, 2014Inventors: Kevin H. Gardner, Laura B. Motta-Mena, Brian D. Zotowski
-
Publication number: 20140314727Abstract: The present invention relates to methods of synthesizing long-chain polyunsaturated fatty acids, especially eicosapentaenoic acid, docosapentaenoic acid and docosahexaenoic acid, in recombinant cells such as yeast or plant cells. Also provided are recombinant cells or plants which produce long-chain polyunsaturated fatty acids. Furthermore, the present invention relates to a group of new enzymes which possess desatorase or elongase activity that can be used in methods of synthesizing long-chain polyunsaturated fatty acids.Type: ApplicationFiled: July 3, 2014Publication date: October 23, 2014Applicant: Commonwealth Scientific and Industrial Research OrganisationInventors: Surinder Pal Singh, Stanley Suresh Robert, Peter David Nichols, Susan Irene Ellis Blackburn, Xue-Rong Zhou, James Robertson Petrie, Allan Graham Green
-
Patent number: 8865966Abstract: Pentameric CRP is produced at a high efficiency by transferring DNA, which encodes monomeric CRP, into a silkworm to thereby construct a transgenic silkworm and then collecting and purifying pentameric CRP that is produced by the transgenic silkworm constructed above.Type: GrantFiled: May 30, 2011Date of Patent: October 21, 2014Assignees: Nitto Boseki Co., Ltd., National Institute of Agrobiological SciencesInventors: Iwao Kiyokawa, Yuji Arimatsu, Toshihide Miura, Ryo Kojima, Hideki Sezutsu, Keiro Uchino, Isao Kobayashi, Toshiki Tamura
-
Publication number: 20140304846Abstract: The present invention relates to the proline rich transmembrane protein 2 (PRRT2) gene, and the identification of mutations and variations in PRRT2 that give rise to seizure and movement disorders. Accordingly, the present invention provides methods for the diagnosis or prognosis of such disorders by identifying alterations in the PRRT2 gene. Identification of alterations in the PRRT2 gene also enables the identification of subjects with an increased likelihood of having an offspring predisposed to such disorders. The present invention also provides an isolated nucleic acid molecule comprising an alteration in the PRRT2 gene, wherein said alteration produces a seizure and/or movement disorder phenotype. Also provided is an isolated PRRT2 polypeptide that comprises an alteration which produces a seizure and/or movement disorder phenotype.Type: ApplicationFiled: October 29, 2012Publication date: October 9, 2014Inventors: Sarah Elizabeth Heron, Leanne Michelle Dibbens, Samuel Frank Berkovic, Ingrid Eileen Scheffer, John Charles Mulley
-
Publication number: 20140296490Abstract: In one aspect, the disclosure relates to antibodies that are highly galactosylated, methods of production of these antibodies and methods of use of these antibodies.Type: ApplicationFiled: August 10, 2012Publication date: October 2, 2014Applicant: Laboratoire Français du Fractionnement et des BiotechnologiesInventors: Valegh Faid, Guillaume Chevreux
-
Publication number: 20140298500Abstract: A polynucleotide encoding a biosensor polypeptide comprising a modified circularly-permuted thermostable luciferase and a linker linking the C-terminal portion of the thermostable luciferase to the N-terminal portion of the thermostable luciferase. The modified circularly-permuted thermostable luciferase is modified relative to a parental circularly-permuted thermostable luciferase. The linker contains a sensor region capable of interacting with a target molecule in a cell. The modified circularly-permuted thermostable luciferase has an enhanced response after interaction of the biosensor with the target molecule relative to the parental circularly-permuted thermostable luciferase in the presence of the target molecule. Alternatively, the modified circularly-permuted thermostable luciferase has an enhanced response after interaction of the biosensor with the target molecule relative to the modified circularly-permuted thermostable luciferase in the absence of the target molecule.Type: ApplicationFiled: May 5, 2014Publication date: October 2, 2014Inventors: Brock Binkowski, Braeden Butler, Lance P. Encell, Frank Fan, Brad Hook, Paul Otto, Gediminas Vidugiris, Susan Wigdal, Kristopher Zimmerman
-
Publication number: 20140298493Abstract: The invention concerns the development of a PIK3CA H1047R knock-in non-human animal breast cancer model, and its use for identification of a spontaneous loss-of-function TP53 mutation involved in spindle cell tumor formation. The invention further concerns the identification of additional somatic mutations and copy number aberrations in the breast tumors using this model, and methods and means for the diagnosis and treatment of breast cancer.Type: ApplicationFiled: July 26, 2012Publication date: October 2, 2014Inventor: Somasekar Seshagiri
-
Publication number: 20140298501Abstract: A modified arthropod, an arthropod-modifying bacterium, and use thereof as an agent for control of diseases transmitted by arthropods, particularly mosquitoes, is provided. More specifically, an isolated arthropod-adapted Wolbachia bacterium capable of modifying one or more biological properties of a mosquito host is provided. The modified arthropod may be characterized as having a shortened life-span, a reduced ability to transmit disease, a reduced susceptibility to a pathogen, a reduced fecundity, and/or a reduced ability to feed from a host, when compared to a corresponding wild-type arthropod.Type: ApplicationFiled: June 14, 2014Publication date: October 2, 2014Inventors: Scott Leslie O'Neill, Conor James McMeniman, Karyn Nicole Johnson, Elizabeth Ann McGraw, Luciano A. Moreira, Peter Anthony Ryan, Brian Herbert Kay, Jeremy Colin Brownlie
-
Publication number: 20140298499Abstract: The invention relates to enzymes having xylanase, mannanase and/or glucanase activity, e.g., catalyzing hydrolysis of internal ?-1,4-xylosidic linkages or endo-?-1,4-glucanase linkages; and/or degrading a linear polysaccharide beta-1,4-xylan into xylose. Thus, the invention provides methods and processes for breaking down hemicellulose, which is a major component of the cell wall of plants, including methods and processes for hydrolyzing hemicelluloses in any plant or wood or wood product, wood waste, paper pulp, paper product or paper waste or byproduct. In addition, methods of designing new xylanases, mannanases and/or glucanases and methods of use thereof are also provided. The xylanases, mannanases and/or glucanases have increased activity and stability at increased pH and temperature.Type: ApplicationFiled: December 16, 2013Publication date: October 2, 2014Applicant: BP Corporation North America Inc.Inventors: Kevin A. Gray, Reinhard Dirmeier
-
Publication number: 20140298502Abstract: The amino acid and nucleic acid sequences of a ?5-desaturase enzyme and a ?8-desaturase enzyme are disclosed. The nucleic acid sequences can be used to design recombinant DNA constructs and vectors. These vectors can then be used to transform various organisms, including for example, plants and yeast. The transformed organisms will then produce polyunsaturated fatty acids. The amino acid sequences are useful for generating enzyme-specific antibodies that are useful for identifying the desaturases.Type: ApplicationFiled: June 18, 2014Publication date: October 2, 2014Applicant: Washington State University Research FoundationInventors: John A. Browse, James G. Wallis, Jennifer L. Watts
-
Publication number: 20140289881Abstract: The present disclosure provides methods and compositions relating to a polynucleotide comprising a dsRNA region that is complementary to a particular region of the NS1 gene segment in the influenza virus genome that targets a sequence comprising two overlapping reading frames, one encoding NS1 and the second encoding the NEP polypeptide. Thus, the polynucleotide of the invention is able to target two message RNAs and is effective at inhibiting the replication of influenza virus in a cell.Type: ApplicationFiled: March 13, 2014Publication date: September 25, 2014Inventors: Timothy James Doran, Scott Geoffrey Tyack
-
Publication number: 20140283154Abstract: The present invention relates to methods of facilitating the expression of recombinant polypeptides from cells, extracellular fluids, extracellular fibers, or any combination thereof, obtained from transgenic insect cells and larvae comprising a bacterial GlcNAc-6-P 2?-epimerase (GNPE), which is capable of converting N-acetyl-D-glucosamine-6-phosphate (GlcNAc-6-P) to N-acetyl-D-mannosamine-6-phosphate (ManNAc-6-P). The invention relates to methods to promote efficient glycoconjugate sialylation, by providing simpler ways to produce large intracellular pools of sialic acid precursors. The invention is also directed to nucleic acids, vectors, and cells comprising nucleic acids encoding polypeptides involved in the synthesis of sialic acid precursors, and cells in combination with nucleic acids encoding glycosyltransferases, including sialyltransferases, to facilitate the production of humanized recombinant glycoproteins.Type: ApplicationFiled: March 14, 2013Publication date: September 18, 2014Inventors: Christoph GEISLER, Donald Jarvis
-
Publication number: 20140283156Abstract: The present invention provides a trans-splicing ribozyme comprising i) a targeting nucleotide sequence that is complementary to a target nucleotide sequence within a mRNA that is expressed in a cell; contiguous with ii) a catalytic RNA sequence; contiguous with iii) a donor transcript, which donor transcript comprises at least a nucleotide sequence that encodes a trans-activator, wherein when the trans-splicing ribozyme is expressed in a cell, the catalytic RNA sequence cleaves the mRNA and ligates the donor transcript to the mRNA to generate a spliced mRNA which comprises the donor transcript, such that the donor transcript is translated as part of the spliced mRNA in the cell, as well as methods of using the trans-splicing ribozyme. The present invention also provides variants of Cre and other recombinases, as well as method of using the variants.Type: ApplicationFiled: March 13, 2014Publication date: September 18, 2014Applicant: COLD SPRING HARBOR LABORATORYInventors: Anthony M. Zador, Ian D. Peikon
-
Publication number: 20140283155Abstract: Disclosed herein are components, systems and methods for regulating population of multicellular organisms, for example insects.Type: ApplicationFiled: March 12, 2014Publication date: September 18, 2014Inventors: Omar S. Akbari, Katie L. Kennedy, Bruce A. Hay
-
Patent number: 8835712Abstract: The present invention provides novel transgenic nonhuman mammals capable of producing human sequence antibodies, as well as methods of producing and using these antibodies.Type: GrantFiled: September 9, 2010Date of Patent: September 16, 2014Assignees: Medarex, L.L.C., Kyowa Hakko Kirin Co., Ltd.Inventors: Kazuma Tomizuka, Isao Ishida, Nils Lonberg, Edward L. Halk
-
Publication number: 20140245466Abstract: The invention provides genetically modified non-human animals that express chimeric human/non-human T cell co-receptor polypeptides (e.g., CD4, CD8?, CD8?), as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same.Type: ApplicationFiled: February 20, 2014Publication date: August 28, 2014Applicant: REGENERON PHARMACEUTICALS, INC.Inventors: Lynn MACDONALD, Andrew J. MURPHY, Naxin TU, Vera VORONINA, Cagan GURER
-
Publication number: 20140245468Abstract: Non-human animals, e.g., mammals, e.g., mice or rats, are provided comprising an immunoglobulin heavy chain locus that comprises a rearranged human immunoglobulin heavy chain variable region nucleotide sequence. The rearranged human immunoglobulin heavy chain variable region nucleotide sequence may be operably linked to a heavy or light chain constant region nucleic acid sequence. Also described are genetically modified non-human animals comprising an immunoglobulin light chain locus comprising one or more but less than the wild type number of human immunoglobulin light chain variable region gene segments, which may be operably linked to a light chain constant region nucleic acid sequence. Also provided are methods for obtaining nucleic acid sequences that encode immunoglobulin light chain variable domains capable of binding an antigen in the absence of a heavy chain.Type: ApplicationFiled: February 20, 2014Publication date: August 28, 2014Applicant: Regeneron Pharmaceuticals, Inc.Inventors: John McWhirter, Cagan Gurer, Karolina A. Meagher, Lynn Macdonald, Andrew J. Murphy
-
Publication number: 20140245467Abstract: The invention provides genetically modified non-human animals that express chimeric human/non-human MHC I and MHC II polypeptides and/or human or humanized ?2 microglobulin polypeptide, as well as embryos, cells, and tissues comprising the same. Also provided are constructs for making said genetically modified animals and methods of making the same. Methods of using the genetically modified animals to study various aspects of human immune system are provided.Type: ApplicationFiled: February 20, 2014Publication date: August 28, 2014Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Lynn MACDONALD, Andrew J. MURPHY, Vera VORONINA, Cagan GURER
-
Publication number: 20140237632Abstract: Nucleic acid compositions encoding rapidly maturing fluorescent proteins, as well as non-aggregating versions thereof (and mutants thereof) as well as the proteins encoding the same, are provided. The proteins of interest are proteins that are fluorescent, where this feature arises from the interaction of two or more residues of the protein. The subject proteins are further characterized in that, in certain embodiments, they are mutants of wild type proteins that are obtained either from non-bioluminescent Cnidarian, e.g., Anthozoan, species or are obtained from Anthozoan non-Pennatulacean (sea pen) species. In certain embodiments, the subject proteins are mutants of wild type Discosoma sp. “red” fluorescent protein. Also of interest are proteins that are substantially similar to, or mutants of, the above specific proteins. Also provided are fragments of the nucleic acids and the peptides encoded thereby, as well as antibodies to the subject proteins and transgenic cells and organisms.Type: ApplicationFiled: January 21, 2014Publication date: August 21, 2014Inventors: BROOKE BEVIS, BENJAMIN GLICK
-
Patent number: 8809617Abstract: The present invention relates to methods and compositions for high content drug screening in C. elegans which may be used to identify compounds that treat disorders associated with protein aggregation.Type: GrantFiled: September 14, 2010Date of Patent: August 19, 2014Assignee: The University of Pittsburgh—of the Commonwealth System of Higher EducationInventors: Stephen C. Pak, David H. Perlmutter, Gary A. Silverman
-
Publication number: 20140223591Abstract: The present disclosure generally relates to methods and compositions for contraception. In some embodiments, vector based approaches for contraception are provided.Type: ApplicationFiled: January 31, 2014Publication date: August 7, 2014Applicant: California Institute of TechnologyInventors: Bruce A. Hay, Juan Li
-
Publication number: 20140223592Abstract: A pig myostatin gene locus and uses thereof are provided. Also provided includes an expression cassette comprising a promoter, a foreign gene and a following terminator; the promoter is a DNA molecule as set forth in any of 1)-4): 1) nucleotides at positions 2642-3778 starting from the 5? end of SEQ ID NO. 1 in the sequence listing; 2) nucleotides as set forth in SEQ ID NO. 1 in the sequence listing; 3) a DNA molecule, hybridizing and having the same function with the DNA sequence as defined in 1) or 2) under stringent condition. Experiments show that the pig myostatin gene locus provides a valuable gene source for gene targeting, as well as introducing and expressing a foreign gene at this site.Type: ApplicationFiled: July 6, 2011Publication date: August 7, 2014Applicant: PIG MYOSTATIN GENE LOCUS AND USES THEREOFInventors: Yanzhen Bi, Xinmin Zheng, Xianfeng Qiao, Ximei Liu, Liping Zhang, Wenjun Hua, Li Li, Hongwei Xiao, Jingrong Zhou, Qingxin Wei
-
Publication number: 20140223590Abstract: An isolated polynucleotide encoding a modified luciferase polypeptide and substrates. The OgLuc variant polypeptide has at least 60% amino acid sequence identity to SEQ ID NO: 1 and at least one amino acid substitution at a position corresponding to an amino acid in SEQ ID NO: 1. The OgLuc variant polypeptide has at least one of enhanced luminescence, enhanced signal stability, and enhanced protein stability relative to the corresponding polypeptide of the wild-type Oplophorus luciferase.Type: ApplicationFiled: January 21, 2014Publication date: August 7, 2014Applicant: Promego CorporationInventors: Brock Binkowski, Lance P. Encell, Mary Hall, Matthew B. Robers, Michael R. Slater, Keith V. Wood, Monika G. Wood
-
Publication number: 20140212416Abstract: The invention provides improved non-human vertebrates and non-vertebrate cells capable of expressing antibodies comprising human variable region sequences. The present invention is directed to the provision of long HCDR3s from non-human vertebrates and cells. The present invention is also directed to the provision of novel V, D and J pairings in immunoglobulin heavy and light chain loci. Novel, biased antibody diversities and potentially expanded diversities are provided. The invention also provides for novel and potentially expanded diversity or diversity that is biased towards variable gene usage common to antibodies useful for treating and/or preventing certain diseases or conditions, such as infectious diseases. The invention also provides methods of generating antibodies using such vertebrates, as well as the antibodies per se, therapeutic compositions thereof and uses.Type: ApplicationFiled: March 19, 2014Publication date: July 31, 2014Applicant: Kymab LimitedInventors: Glenn Friedrich, E-Chiang Lee, Jasper Clube, Nicholas England
-
Publication number: 20140206843Abstract: This invention relates to the biotechnology area, and provides a kind of TRAIL chimeric protein, DNA sequence encoding this chimeric protein, vectors comprising this DNA, host cells or transgenic animals that contain one of the vectors, and preparation methods for the said chimeric protein and its applications. The said TRAIL fusion protein from the N to C terminal comprises human leucine zipper sequence, human TRAIL protein, human TRAIL extracellular domain or a fragment thereof. The chimeric protein has significantly enhanced stability, prolonged half-life in animals, increased efficacy and thus has broad application future.Type: ApplicationFiled: January 27, 2014Publication date: July 24, 2014Applicant: Magellan Pharma Co. Ltd.Inventors: Bing ZHOU, Yu ZHOU, Jing JIANG
-
Patent number: 8785718Abstract: Methods of using hypermethylated transposons to create genetically modified animals that express interfering RNAs are described.Type: GrantFiled: October 5, 2012Date of Patent: July 22, 2014Assignee: Recombinetics, Inc.Inventors: Scott C. Fahrenkrug, Daniel F. Carlson, Aron M. Geurts
-
Patent number: 8785717Abstract: Genetically modified mammals are described which lack the mannan binding lectin associated serine protease MASP-2, together with methods and constructs for their production. Such mammals are useful as models for disorders of the complement system, and in the identification of treatments for such disorders. Also described are mammals which lack the associated protein MAp19; such mammals may also lack MASP-2.Type: GrantFiled: June 8, 2005Date of Patent: July 22, 2014Assignee: University of LeicesterInventors: Teizo Fujita, Hans-Wilhelm Schwaeble, Cordula Margaret Stover
-
Patent number: 8779231Abstract: The present invention relates to a recombinant vector and a transgenic mouse for expressing human ferritin in a tissue non-specific manner, and more particularly, to a vector prepared by operably linking a human ferritin gene to a promoter including a cytomegalovirus (CMV) early enhancer element and a ?-actin promoter, and a transgenic mouse expressing human ferritin in a tissue non-specific manner, which is transformed with the vector. Further, the present invention relates to a method for preparing a transgenic mouse, and a method for monitoring cell or tissue therapy using the transgenic mouse.Type: GrantFiled: July 7, 2011Date of Patent: July 15, 2014Assignee: SNU R&DB FoundationInventors: Woo Kyung Moon, Hoe Suk Kim
-
Patent number: 8779236Abstract: Methods are disclosed for screening for the occurrence of gene silencing (e.g., post transcriptional gene silencing) in an organism. Also provided are methods for isolating silencing agents so identified.Type: GrantFiled: July 23, 2009Date of Patent: July 15, 2014Assignee: Plant Bioscience LimitedInventors: David Charles Baulcombe, Andrew John Hamilton
-
Publication number: 20140189898Abstract: The present invention provides a method of identifying an animal having a genotype associated with resistance to bacterial infection comprising the steps of: (a) providing a sample from said animal; (b) determining the alleles at one or more markers of the SAL1 locus to identify the genotype of the marker, wherein said SAL1 locus lies between 54.0 MB to 54.8 MB of chicken Chromosome 5 or an equivalent thereof; and (c) determining whether the genotype is a genotype associated with resistance to bacterial infection.Type: ApplicationFiled: March 6, 2014Publication date: July 3, 2014Applicant: The Pirbright InstituteInventors: Mark Fife, Peter Kaiser, Nigel Salmon
-
Patent number: 8766034Abstract: This invention relates transgenic animals that overexpress TL1A in a tissue specific manner to model inflammatory bowel disease (IBM such as colitis, Crohn's disease and ulcerative colitis, fibrosis, and related inflammatory diseases and conditions. TL1A transgenic animals constitutively express both TL1A and GFP in lymphoid and myeloid cell lineages, allowing convenient identification and sorting of immune cells involved in IBD disease progression, such as T-cells, antigen presenting cells (APC), and dendritic cells (DC). TL1A transgenic animals may be induced to exhibit gross fibrosis, or isolated cells may be implanted into immunodeficient mice to establish colitis.Type: GrantFiled: September 22, 2011Date of Patent: July 1, 2014Assignee: Cedars-Sinai Medical CenterInventors: David Q. Shih, Stephen R. Targan
-
Publication number: 20140161793Abstract: A conjugate molecule comprising an oligo- or polysaccharide covalently bound to a carrier and its use as potential vaccine against infection by S. Flexneri.Type: ApplicationFiled: December 14, 2011Publication date: June 12, 2014Applicants: INSERM, INSTITUT PASTEUR, Centre National De La Recherche ScientifiqueInventors: Armelle PHALIPON, Farida NATO, Laurence MULARD, Philippe SANSONETTI, Francoise BALEUX, Frederic BELOT, Cyrille GRANDJEAN
-
Transferases and Oxidoreductases, Nucleic Acids Encoding Them and Methods for Making and Using Them.
Publication number: 20140165221Abstract: This invention relates generally to enzymes, polynucleotides encoding the enzymes, the use of such polynucleotides and polypeptides and more specifically to enzymes having transferase activity, e.g., transaminase activity, e.g., d-amino-acid transferase activity, and/or oxidoreductase activity, e.g., dehydrogenase activity, e.g., d-amino-acid dehydrogenase activity, and/or catalyze the transfer of a chemical group, catalyze transamination, catalyze the reaction: D-alanine+2-oxoglutarate<=>pyruvate+D-glutamate, and/or catalyze an oxidation-reduction reaction, catalyze the removal of hydrogen atoms, and/or catalyze the reaction: D-amino acid+H2O+acceptor<=>a 2-oxo acid+NH3+reduced acceptor.Type: ApplicationFiled: February 18, 2014Publication date: June 12, 2014Applicant: VERENIUM CORPORATIONInventors: DAVID P. WEINER, PETER LUGINBUHL, ANALIA BUENO, JOSLIN M. CUENCA, ERIN MARASCO -
Publication number: 20140130192Abstract: The present invention provides materials and methods for treating Alzheimer's disease and other tau related neurodegenerative disorders. A tau kinase, Brain Derived Tau Kinase (BDTK) is provided. BDTK can cause hyperphosphorylation of tau protein, which leads to formation of neurofibrillary tangles, which are implicated in the degenerative symptoms of Alzheimer's and other neurodegenerative disorders. Methods of diagnosis and treatment based on the discovery of this novel tau kinase are also provided.Type: ApplicationFiled: December 31, 2013Publication date: May 8, 2014Applicant: Unemed CorporationInventor: Tsuneya Ikezu
-
Publication number: 20140128800Abstract: Provided herein is a chimeric photoactivatable polypeptide comprising an opsin membrane receptor, wherein an intracellular domain of the opsin membrane receptor is replaced with a corresponding intracellular domain of a chemokine receptor, a sphingosine-1-phosphate receptor or an ATP receptor and uses thereof. Further provided are methods of treating cancer, injury of the nervous system, autoimmune disease, and graft rejection comprising administering to the subject a cell that expresses the chimeric photoactivatable polypeptide and exposing the cell to a visible light source.Type: ApplicationFiled: June 28, 2012Publication date: May 8, 2014Applicant: UNIVERSITY OF ROCHESTERInventor: Minsoo Kim
-
Publication number: 20140123330Abstract: A genetically modified livestock animal comprising a genome that comprises inactivation of a neuroendocrine gene selective for sexual maturation, with the inactivation of the gene preventing the animal from becoming sexually mature. Methods of using, and processes of making, the animals are taught.Type: ApplicationFiled: October 30, 2013Publication date: May 1, 2014Inventors: Daniel F. Carlson, Scott C. Fahrenkrug, Xavier Lauth
-
Publication number: 20140120089Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), which is preferably human IGF-IR. The invention also relates to human anti-IGF-IR antibodies, including chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulin molecules derived from anti-IGF-IR antibodies and nucleic acid molecules encoding such molecules. The present invention also relates to methods of making anti-IGF-IR antibodies, pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-IGF-IR antibodies.Type: ApplicationFiled: December 19, 2013Publication date: May 1, 2014Applicants: PFIZER INC., AMGEN FREMONT INC.Inventors: Bruce D. Cohen, Jean Beebe, Jr., Penelope E. Miller, James D. Moyer, Jose Ramon Corvalan, Michael Gallo
-
Publication number: 20140115727Abstract: The invention relates to a novel antibody capable of binding specifically to the human c-Met receptor and/or capable of specifically inhibiting the tyrosine kinase activity of said receptor both in a ligand-dependent and in a ligand-independent manner, with an improved antagonistic activity, said antibody comprising a modified hinge region. The invention also relates to a composition comprising such an antibody antagonist to c-Met and its use as a medicament for treating cancer.Type: ApplicationFiled: August 29, 2013Publication date: April 24, 2014Applicant: Pierre Fabre MedicamentInventors: Liliane Goetsch, Thierry Wurch, Cedric Bes
-
Publication number: 20140112904Abstract: A method for enhancing the cleavage activity of an I-CreI derived meganuclease, comprising the site-specific mutation of at least one amino acid residue which is selected in the group consisting of: the glycine at position 19, the phenylalanine at position 54, the phenylalanine at position 87, the serine at position 79, the valine at position 105 and the isoleucine at position 132 of I-CreI, and its application for the manufacturing of meganuclease cleaving a DNA target of interest, for use in genome therapy (treatment of genetic diseases) and genome engineering (making of transgenic animals, transgenic plants and recombinant cell lines).Type: ApplicationFiled: June 6, 2008Publication date: April 24, 2014Applicant: CellectisInventors: Sylvestre Grizot, Agnes Gouble, Christophe Perez-Michaut
-
Publication number: 20140115726Abstract: The present invention relates to new Transcription Activator-Like Effector proteins and more particularly new Transcription Activator-Like Effector Nucleases (TALENs) that can efficiently target and process nucleic acids. The present invention also concerns methods to use these new Transcription Activator-Like Effector proteins. The present invention also relates to vectors, compositions and kits in which Transcription Activator-Like Effector proteins of the present invention are used.Type: ApplicationFiled: April 5, 2012Publication date: April 24, 2014Applicant: CELLECTISInventors: Philippe Duchateau, Alexandre Juillerat, Julien Valton, Claudia Bertonati, Jean-Charles Epinat, George H. Silva
-
Patent number: 8704037Abstract: The present invention provides compositions and methods for studying neuropathy. The compositions and methods provided herein are particularly useful for screening agents of therapeutic and/or diagnostic potential.Type: GrantFiled: December 21, 2011Date of Patent: April 22, 2014Assignee: Case Western Reserve UniversityInventors: Stephen M. Selkirk, Robert H. Miller
-
Patent number: 8703485Abstract: The invention relates to transgenic animals lacking endogenous Ig and capable of producing transgenic antibodies, as well as methods of making the same. The invention further relates to methods for producing transgenic antibodies in such animals, and transgenic antibodies so produced.Type: GrantFiled: May 30, 2008Date of Patent: April 22, 2014Assignee: OMT, Inc.Inventor: Roland Buelow
-
Publication number: 20140099325Abstract: In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucleotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4, are provided. Further provided are antibodies having similar binding properties and antibodies (or other antagonists) having similar functionality as antibodies disclosed herein.Type: ApplicationFiled: June 18, 2013Publication date: April 10, 2014Inventors: Douglas Charles Hanson, Mark Joseph Neveu, Eileen Elliott Mueller, Jeffrey Herbert Hanke, Steven Christopher Gilman, C. Geoffrey Davis, Jose Ramon Corvalan
-
Patent number: 8692052Abstract: A mouse with a humanization of the mIL-3 gene and the mGM-CSF gene, a knockout of a mRAG gene, and a knockout of a mII2rg subunit gene; and optionally a humanization of the TPO gene is described. A RAG/II2rg KO/hTPO knock-in mouse is described. A mouse engrafted with human hematopoietic stem cells (HSCs) that maintains a human immune cell (HIC) population derived from the HSCs and that is infectable by a human pathogen, e.g., S. typhi or M. tuberculosis is described. A mouse that models a human pathogen infection that is poorly modeled in mice is described, e.g., a mouse that models a human mycobacterial infection, wherein the mouse develops one or more granulomas comprising human immune cells. A mouse that comprises a human hematopoietic malignancy that originates from an early human hematopoietic cells is described, e.g., a myeloid leukemia or a myeloproliferative neoplasia.Type: GrantFiled: September 14, 2012Date of Patent: April 8, 2014Assignees: Regeneron Pharmaceuticals, Yale University, Institute for Research in Biomedicine (IRB)Inventors: Sean Stevens, Andrew J. Murphy, Richard Flavell, Elizabeth Eynon, Jorge Galan, Tim Willinger, Markus Manz, Anthony Rongvaux, George D. Yancopoulos